Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital

Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low-dose pirfenidone (that is, less than 1200 mg/day). We retrospectively reviewed the medical records of patients with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2020-12, Vol.10 (1), p.21218, Article 21218
Hauptverfasser:	Song, Myung Jin, Moon, Sung Woo, Choi, Ji Soo, Lee, Sang Hoon, Lee, Su Hwan, Chung, Kyung Soo, Jung, Ji Ye, Kang, Young Ae, Park, Moo Suk, Kim, Young Sam, Chang, Joon, Kim, Song Yee
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/409 692/699/1785 Aged Anorexia Anorexia - complications Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Disease Progression Dyspepsia Dyspepsia - complications Eating disorders Female Fibrosis Gastrointestinal tract Hospitals, University Humanities and Social Sciences Humans Idiopathic Pulmonary Fibrosis - drug therapy Lung diseases Male Medical records Middle Aged multidisciplinary Nausea Nausea - complications Patients Pulmonary fibrosis Pyridones - administration & dosage Pyridones - adverse effects Pyridones - therapeutic use Retrospective Studies Science Science (multidisciplinary) Tertiary Care Centers Treatment Outcome Vital Capacity - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low-dose pirfenidone (that is, less than 1200 mg/day). We retrospectively reviewed the medical records of patients with IPF. The patients were divided into the following three groups, those who were not treated with pirfenidone (control) and those who were treated with pirfenidone at doses
ISSN:	2045-2322 2045-2322
DOI:	10.1038/s41598-020-77837-x